HMGA2 overexpression in non-small cell lung cancer
HMGA2 overexpression in non-small cell lung cancer
复制标题
DOI：
10.1002/mc.20235
复制
发表时间：
2007-07-01
影响因子：
4.6
通讯作者：
Bullerdiek, Joern
中科院分区：
文献类型：
--
作者：
Meyer, Britta;Loeschke, Siegfried;Bullerdiek, Joern
肺癌仍然是全世界癌症死亡的主要原因，这主要是因为大多数肺癌是在晚期被诊断出来的。高迁移率族蛋白HMGA2在多种恶性肿瘤中均有过表达，且常与预后不良有关。本研究采用实时定量RT-PCR方法检测了17例腺癌(AC)和17例鳞癌(SCC)配对的癌和非癌肺组织中HMGA2的表达水平。将转录水平与免疫组织化学(IHC)结果进行比较。定量逆转录聚合酶链式反应检测到HMGA2在所有标本中均有表达，在癌组织中的表达范围为5422~16991545拷贝/250 ng总RNA，在非癌组织中的表达范围为289~525947拷贝/250 ng。在34例非小细胞肺癌中，有33例HMGA2过度表达，在非肿瘤性和肿瘤性标本中，AC(P<；0.0001)和鳞癌(P<；0.0001)均有高度统计学意义的差异。表达差异很大，在AC和SCC中的表达分别增加了911倍和2504倍，其中SCC的表达增加更显著(P<；0.05)。提示HMGA2在NSCLC中的过度表达是一种常见事件，可作为肺癌的分子标志物。(C)2007年Wiley-Liss，Inc.
Lung cancer is still the leading cause of death from cancer worldwide primarily because of the fact that most lung cancers are diagnosed at advanced stages. Overexpression of the high mobility group protein HMGA2 has been observed in a variety of malignant tumors and often correlates with poor prognosis. Herein, HMGA2 expression levels were analyzed in matching cancerous and non-cancerous lung samples of 17 patients with adenocarcinoma (AC) and 17 patients with squamous cell carcinoma (SCC) with real-time quantitative RT-PCR (qRT-PCR). Transcript levels were compared to results obtained by immunohistochemistry (IHC). HMGA2 expression was detectable by qRT-PCR in all samples tested and varied from 5422 to 16 991 545 copies per 250 ng total RNA in the carcinoma samples and from 289 to 525947 copies in the non-cancerous tissue samples. In 33/34 non-small cell lung cancer (NSCLC) samples tested, an overexpression of HMGA2 was revealed with statistically highly significant differences between nonneoplastic and tumor samples for both AC (P < 0.0001) as well as for SCC (P< 0.0001). Expression varies strongly and is increased up to 911 -fold for AC and up to 2504-fold for SCC, respectively, with statistically significant higher increase in SCC (P < 0.05). The results presented herein indicate that HMGA2 overexpression is a common event in NSCLC and could serve as molecular marker for lung cancer. (C) 2007 Wiley-Liss, Inc.